Table 4.
Ongoing clinical trials targeting P53/SMAD4/CDKN2A pathways for the treatment and diagnosis of pancreatic cancer.
| Trial ID | Target gene | Tested drugs | Treatment setting | Phase | Study type | Status | Primary outcomes |
|---|---|---|---|---|---|---|---|
| NCT02340117 | TP53 | SGT-53, nab-paclitaxel, gemcitabine | Stage IV metastatic PDAC | II | Interventional | Recruiting | PFS at 5.5 months |
| NCT02432963 | TP53 | p53MVA vaccine and pembrolizumab | Uncontrolled solid tumors with p53 overexpression or mutations | I | Interventional | Active, not recruiting | Tolerability |
| NCT02433626 | TP53 | COTI-2 and cisplatin | Advanced or recurrent malignancies | I | Interventional | Recruiting | Number of DLTs and Tmax in 6 months |
| NCT03095781 | HSP90 | XL888 and pembrolizumab | Advanced gastrointestinal malignancies | I | Interventional | Recruiting | Recommended phase II dose |
| NCT03221400 | HSP90 | PEN-866 sodium | PDAC and advanced solid malignancies | I/IIa | Interventional | Recruiting | DLTs, AEs and efficacy |
| NCT02194829 | Wee-1 | MK-1775 | Untreated PC | I/II | Interventional | Active, not recruiting | MTD and PFS |
| NCT03666832 | TGF-β | TEW-7197, FOLFOX | Metastatic PDAC who have failed in first-line chemotherapy | I/II | Interventional | Recruiting | PFS |
| NCT03454035 | CDK4/6 | Ulixertinib, palbociclib | Previously treated metastatic PC and other solid tumors | I | Interventional | Recruiting | MTD and OS |
| NCT03065062 | CDK4/6 | Palbociclib, gedatolisib | Pancreatic, and other solid tumors | I | Interventional | Recruiting | MTD, recommended phase II dose and AEs |
| NCT03891784 | CDK4/6 | Abemaciclib | Metastatic neuroendocrine tumors in the digestive system | II | Interventional | Recruiting | ORR |
| NCT03524677 | KRAS, CDKN2A, P53, SMAD4 | KRAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA | Non-metastatic PC | – | Observational | Recruiting | Vascular invasion and early recurrence |
The data originated from https://clinicaltrials.gov (accessed July 29, 2020).